| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2080029 | Drug Discovery Today | 2012 | 5 Pages |
Abstract
Recent changes to non-clinical cancer guidelines offer a golden opportunity to expedite the translation of new anticancer drugs into the clinic. In this review we look at how these guidelines can be implemented and how they can be integrated with non-clinical and clinical study design to produce robust and safe clinical trials.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Paul S. Jones, David Jones,